Evidence map›Paper›PMID 42426387›Full record

Observational studySurgical endoscopy2026

Effect of two-week perioperative glucagon-like peptide-1 receptor agonist interruption on retained gastric contents during esophagogastroduodenoscopy: a retrospective, observational study.

Zhiyu Dong, Ouyang Li, Jiajun Wu, Yanglei Li, Zili Xiao, Feng Li, Tao Sun, Jun Zhou, Weidong Gu, Danian Ji

Abstract readObservational Study
PubMed Publisher
In one paragraph

Observational study in Surgical endoscopy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhiyu Dong *Department of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China.
Ouyang Li *Department of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China.
Jiajun Wu *Department of Anesthesia, Huadong Hospital, Fudan University, Shanghai, China.
Yanglei LiDepartment of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China.
Zili XiaoDepartment of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China.
Feng LiDepartment of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China.
Tao SunDepartment of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China.
Jun ZhouDepartment of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China.
Weidong GuDepartment of Anesthesia, Huadong Hospital, Fudan University, Shanghai, China. mcwgwd@163.com.
Danian JiDepartment of Gastrointestinal Endoscopy, Huadong Hospital, Fudan University, Shanghai, China. arctg4@163.com.

Funding

Huadong Hospital Key Discipline Project ZDXK2210National Natural Science Foundation of China 82271286National Natural Science Foundation of China 82400624Shanghai Municipal Health Commission 202440154Shanghai Municipal Health Commission 20244Y0151
6 · The paper itself

Abstract

backgroundGlucagon-like peptide-1 receptor agonists (GLP-1RAs) slow gastric emptying and may therefore increase the risk of retained gastric contents (RGC). The optimal duration of discontinuation before esophagogastroduodenoscopy (EGD) under sedation or general anesthesia remains controversial.

methodsWe conducted a single-center, retrospective, observational study of patients who underwent elective EGD between August 2023 and May 2025. According to GLP-1RA exposure, patients were classified as (i) no GLP-1RA use, (ii) GLP-1RA continued use, or (iii) GLP-1RA two-week hold. The primary outcome was the presence of RGC, defined as any solid residue or > 100 mL of fluid visualized during EGD. Multivariate logistic regression was used to explore the relationship between GLP-1RA use and RGC.

resultsRGC occurred in 0.4% (63/15902) of patients with no GLP-1RA use, 5.83% (6/103) of patients with GLP-1RA continued use, and 1.61% (1/62) of patients with GLP-1RA two-week hold. GLP-1RA continued use was associated with a tenfold higher RGC risk versus no GLP-1RA use (odds ratio [OR] 10.68, 95% CI 3.74-30.55; p < 0.001), whereas a two-week hold reduced risk to a level statistically comparable with no GLP-1RA use (OR 2.99, 95% CI 0.37-23.89, p = 0.302). Obesity (BMI ≥ 28 kg/m

conclusionsA two-week hold of GLP-1RA lowered RGC incidence to a low level comparable with no GLP-1RA use, especially in normal-weight or overweight patients and in those undergoing concurrent colonoscopy, but may be insufficient for obesity.

Indexed as

Endoscopy, Digestive SystemGastrointestinal ContentsGlucagon-Like Peptide-1 Receptor AgonistsTreatment InterruptionAdultAgedFemaleHumansMaleMiddle AgedRetrospective StudiesGlucagon-Like Peptide-1 Receptor AgonistsColonoscopyEsophagogastroduodenoscopyGLP-1 receptor agonistObesityRetained gastric contents

Identifiers

PMID42426387

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.